Objective: The Hexvix® Observational Patients Evaluation (HOPE) study was designed to determine the extent of distribution of the use of hexaminolevulinate in the diagnosis of non-muscle invasive bladder cancer (NMIBC) and assess patient and treatment characteristics associated with different endoscopic modalities and to address the French authorities' request for information on routine practices for NMIBC diagnosis and surveillance. Patients and Methods: A prospective, observational study in 30 centres in France with fluorescence endoscopy equipment available. All candidates for endoscopy with transurethral resection who gave their consent were eligible. The primary endpoint was the proportion of patients with an NMIBC diagnosis performed with hexaminolevulinate. Results: 506 patients were included: 252 (49.8%) diagnosed with hexaminolevulinate and 254 (50.2%) with white-light endoscopy alone. There were more patients with tumour recurrence, multiple lesions, lesions with a diameter <3 cm, stage Ta disease, and grade 1 lesions in the hexaminolevulinate group. The first quartile median recurrence-free survival time was 310 days in the hexaminolevulinate group and 144 days in the standard-endoscopy group (p = 0.0015). Conclusion: Hexaminolevulinate was in frequent use in France with specific patient and disease characteristics associated with its use. HOPE illustrates the type of data that can be gained in post-authorisation studies to address requests from European health authorities.

Journal Section:
Editor's choice
Keywords:
European Union regulation, Observational studies, Hexaminolevulinate, Non-muscle invasive bladder cancer
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403.
2.
Pfister C, Roupret M, Neuzillet Y, Larre S, Pignot G, Quintens H, Houede N, Comperat E, Colin P, Roy C, Davin JL, Guy L, Irani J, Lebret T, Coloby P, Soulie M; Les membres du CCAFU: [CCAFU Recommendations 2013: bladder carcinoma]. Prog Urol 2013;23(suppl 2):S105-S125.
3.
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-1330.
4.
Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA: The economic consequences of prostate and bladder cancer in the UK. BJU Int 2005;95:59-63.
5.
Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ: A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68-73.
6.
Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, Kurth KH: Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862-866.
7.
Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, van den Bergh H, Leisinger HJ: Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol 2003;170:226-229.
8.
Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, Thanos A, Deliveliotis C: Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 2012;80:354-359.
9.
Lapini A, Minervini A, Masala A, Schips L, Pycha A, Cindolo L, Giannella R, Martini T, Vittori G, Zani D, Bellomo F, Cosciani Cunico S: A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surg Endosc 2012;26:3634-3641.
10.
Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P: Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 2012;109:549-556.
11.
Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M: Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58-62.
12.
Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S: Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011;108:E297-E303.
13.
Yang LP: Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. Mol Diagn Ther 2014;18:105-116.
14.
Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgues JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846-854.
15.
Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 supplementing Directive 2001/83/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council as regards situations in which post-authorisation efficacy studies may be required Text with EEA relevance. Official Journal of the European Union, 10 April 2014.
16.
Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M; le groupe Intérêt de santé publique et études post-inscription (ISPEP): [French Health Authority (HAS) Guidance: the post-registration studies on health technologies (drugs, medical devices and instruments): principles and methods]. Therapie 2012;67:409-421.
17.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-465; discussion 475-467.
18.
Bamberger M, Moore N, Lechat P; participants of Round Table N° 3 of Giens XXVI: How to improve the clinical development paradigm and its division into phases I, II and III. Therapie 2011;66:331-334, 327-330.
19.
Palou J, Hernandez C, Solsona E, Abascal R, Burgues J, Rioja C, Cabrera J, Gutierrez C, Rodriguez O, Iborra I, Herranz F, Abascal J, Conde G, Oliva J: Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. BJU Int 2014;116:37-43.
20.
Bach T, Bastian PJ, Blana A, Kaminsky A, Keller S, Knoll T, Lang C, Promnitz S, Ubrig B, Keller T, Qvick B, Burger M; OPTIC III Study Group: Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III. World J Urol 2017;35:737-744.
21.
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M: Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-980.
22.
Roupret M, Neuzillet Y, Masson-Lecomte A, Colin P, Comperat E, Dubosq F, Houede N, Larre S, Pignot G, Puech P, Roumiguie M, Xylinas E, Mejean A: [CCAFU french national guidelines 2016-2018 on bladder cancer]. Prog Urol 2016;27(suppl 1):S67-S91.
23.
Nakamura Y, Yoshida S, Tanaka H, Inoue M, Ito M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K: Potential utility of Diffusion-Weighted Magnetic Resonance Imaging in diagnosis of residual bladder cancer before second transurethral resection. Urol Int 2017;98:298-303.
24.
Novotny V, Froehner M, Ollig J, Koch R, Zastrow S, Wirth MP: Impact of adjuvant intravesical Bacillus Calmette-Guérin treatment on patients with high-grade T1 bladder cancer. Urol Int 2016;96:136-141.
25.
Marteau F, Kornowski A, Bennison C, Tempest MJ, Mariappan P, Witjes JA: Cost-effectiveness of the optical imaging agent hexaminolevulinate for patients undergoing initial transurethral resection of non-muscle invasive bladder cancer tumours. Eur Urol Suppl 2013;12:125.
26.
Bennison C, Tempest MJ, Marteau F, et al: How investment in hexaminolevulinate technology would be beneficial to patients and healthcare system in non-muscle invasive bladder cancer in Italy? Paper presented at: 10th Health Technology Assessment International Annual Meeting, 2013, Seoul, Korea.
27.
Roupret M, Malavaud B, Molinier L, Leleu H, Blachier M, Marteau F: [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France]. Prog Urol 2015;25:256-264.
28.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J: Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer. Arnhem, Eur Assoc Urol, 2009.
29.
Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642-1649.
30.
Di Leo A, Bleiberg H, Buyse M: Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003;21:2045-2047.
31.
Negrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ: Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 2014;50:1766-1771.
32.
Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC: Evaluation of patient reporting of adverse drug reactions to the UK “Yellow Card Scheme”: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health technology assessment 2011;15:1-234, iii-iv.
33.
Gnadinger M, Mellinghoff HU: The out-of-focus bias in drug surveillance. Eur J Clin Pharmacol 2013;69:357-359.
34.
O'Neill RT: Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. Stat Med 1998;17:1851-1858; discussion 1859-1862.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.